Scientific Team

The Scientific Team at BerGenBio is responsible for conducting cutting-edge research to develop and optimize first-in-class AXL inhibitors. Comprised of expert Scientific Advisors, the team focuses on understanding disease mechanisms, designing experimental studies, and translating scientific findings into clinical applications to combat advanced, treatment-resistant cancers.